Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 50 Medical VC Funds in Switzerland

Last updated: Apr 2024 A list of 50 VC funds that invest in Medical startups based in Switzerland. We rank investors based on the number of investments they made in Medical companies from Switzerland. We update this investor list every month.

Top 50 Medical VC Funds in Switzerland

Investor	Medical Switzerland investments
Zürcher Kantonal Bank	17
Verve Ventures	13
Foundation for Technological Innovation (FIT)	9
BioMedPartners	6
StartAngels Network	5
BlueOcean Ventures	5
Swisscom Ventures	5
Sofinnova Partners	4
New Enterprise Associates	4
Versant Ventures	4
3wVentures	4
Eclosion SA	4
4FO Ventures	4
Polytech Ventures	4
GoBeyond	4
Sunstone Life Science Ventures	4
Fongit Seed Invest	4
SICTIC	3
Endeavour Vision	3
M Ventures	3
OrbiMed	3
Bernina BioInvest	3
Founderful	3
Broadview Ventures	3
Zühlke Ventures AG	3
Index Ventures	3
VINCI CAPITAL	3
EIT Health	3
Gilde Healthcare	3
Inserm Transfert Initiative	3
EQT Life Sciences	3
Alpana Ventures	3
Schroder Adveq	3
Grazia Equity	2
Baszucki Group	2
Bpifrance	2
Reference Capital SA	2
The William K. Warren Foundation	2
VI Partners	2
Viva BioInnovator	2
R42 Group	2
EVA Basel	2
Innosuisse	2
Boundary Holding	2
Ysios Capital	2
Novartis Venture Fund	2
Lichtsteiner Foundation	2
Healthspan Capital	2
Boehringer Ingelheim Venture Fund	2
ORTHO INNOVATIONS	2

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Zürcher Kantonalbank - as an independent, incorporated public-law institution - is wholly owned by the canton of Zurich.

Investment focus

Health Care, Medical Device, Biotechnology
Seed, Series A, Funding Round
Switzerland, Japan, Spain

Portfolio highlights

Odne — Curing with light
ARTIRIA Medical — Artiria Medical empowers catheters and guidewires. We develop cutting edge technologies to revolutionize the limits of neurointerventional procedures, enabling a seamless navigation and stroke treatment.
Cultivated Biosciences — Cultivated - Creamy, dairy-free indulgence

Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.

Investment focus

Health Care, Software, Biotechnology
Series A, Seed, Series B
Switzerland, Germany, France

Portfolio highlights

Aktiia — Founded in Switzerland in May 2018 out of a passion to turn insights into action in the fight against hypertension, Aktiia’s groundbreaking medical technology provides people and their physicians comprehensive insights into blood pressure patterns that will inform the diagnosis and management of hypertension. Now available in the United Kingdom,Aktiia has received its CE Mark as a Class IIa medical device - signifying that the device has been assessed to meet high safety, health and environmental protection requirements in Europe. To learn more, visit Aktiia.com.
Groover — Groover is the best way to promote your music to blogs, radios, record labels, & Spotify playlisters. Get listened to, receive coverage & guaranteed feedback!
ARTIRIA Medical — Artiria Medical empowers catheters and guidewires. We develop cutting edge technologies to revolutionize the limits of neurointerventional procedures, enabling a seamless navigation and stroke treatment.

The Foundation for Technological Innovation (FIT) has been helping startups since 1994, encourages entrepreneurship & supports innovation.

Investment focus

Health Care, Biotechnology, Information Technology
Debt Financing, Grant, Seed
Switzerland, France

Portfolio highlights

Voltiris — Voltiris filters natural sunlight to transmit it to plants and recycle the "wasted" sunlight into green electricity.
PeriVision — At Perivision, we combine artificial intelligence (AI), virtual reality (VR) and the cloud to build the next generation systems to understand visual function. Our systems improve workflow efficiency in practices and hospitals and provide deeper clinical insight into eye diseases.
SwissInspect — SwissInspect is a platform for traceable structural digital twins of infrastructure. Detect and quantify damage using state of the art ai models.

BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
Switzerland, Germany, France

Portfolio highlights

Tricares — TRiCares is a medical device company, devoted to developing a catheter-based valve replacement system for minimal invasive treatment of tricuspid valve regurgitation.
ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and

StartAngels Network is a Zurich-based angel investment firm that provides investment consulting services.

Investment focus

Medical Device, Health Care, Medical
Seed, Series A, Series B
Switzerland, Brazil

Portfolio highlights

Medyria — Medyria is a Swiss medtech startup that engineers technologies for cardiovascular catheter navigation and sensing. They develop a unique guiding and sensing medical device based on proprietary Blood Flow Velocity Sensor technology. The TrackCath System is designed to be cost-effective and safe during EVAR procedures.Medyria's goal is todevelop devices that enable safer and more effective endovascular procedures. It was founded in 2014 and is based in Winterthur, Zurich, Switzerland.
Pipra — PIPRA AG (Pre-Interventional Preventive Risk assessment) is developing a cutting-edge AI-based pre-operative test to assess a patient's risk of suffering from cognitive disorders after surgery.
Hylomorph — Hylomorph is a clinical-stage medical device company developing innovative materials designed to transform the biocompatibility of implantable medical devices.

BlueOcean Ventures SA provides capital, operational and company development advisory support (mentoring, company management, divestment experience, network, negotiation support) to entrepreneurs in Switzerland. BlueOcean Ventures is based in Geneva, Switzerland.

Investment focus

Health Care, Medical, Personal Health
Series A, Seed, Series B
Switzerland, India, France

Portfolio highlights

nPloy — Simply set your filters and get matched with your dream job! Let top employers apply for you & connect with them via chat or a video call.
CyanoGuard AG — Our award-winning cyanide testing and optimizing solution is ideal for the mining, food, and medical field. It's easy to use, digital and offers real-time data.
99RetailStreet — 99RetailStreet is an eCommerce Cloudplatform for the unorganized Retail business in the developing countries. Our ecosystem targets Retailers, Distributors, and Manufacturers. 99RetailStreet provides POS solutions to Retailers, Real-Time Analytics to Manufacturers and Distributors

Swisscom Ventures is an venture capital arm of Swisscom AG, that specializes in early stage tech investments founded in 2007.Swisscom Ventures invests in growth companies with emerging business models and technologies of strategic relevance to Swisscom's core business. As a value-add investor, Swisscom brings its investees the technicalexpertise and strategic insights of an incumbent telecom operator. We act as a bridge to Swisscom's operational business units, which portfolio companies can also leverage as a test environment for their products and services.Swisscom Ventures seeks minority stakes in companies related to the information/communications/entertainment space.

Investment focus

Software, SaaS, Information Technology
Funding Round, Series B, Series A
Switzerland, United States, United Kingdom

Portfolio highlights

rready — Boost internal innovation and engage employees with ready-to-use programs, accompanied by experts in intrapreneurship.
Pexapark — We make PPAs for renewables simple. Master your wind and solar power purchase agreements and get the tools to manage merchant risk.
Spacetek Technology AG — Our process control instruments measure gases in real time, delivering a full quantitative chemical analysis up to ten times per second.

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
France, United States, United Kingdom

Portfolio highlights

Cure51 — Cure51 mission is to create a database of cancer survivors to leverage their exceptional biological features and find new drugs to cure Cancer.
Bioptimus — Our mission is to build the first universal AI foundation model for biology to fuel breakthrough discoveries and accelerate innovations in biomedicine and beyond.
MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas

Foundational partners to ambitious founders at every stage of company-building.

Investment focus

Software, Health Care, Biotechnology
Series B, Series A, Series C
United States, India, China

Portfolio highlights

Wonder — Introducing a new kind of home dining experience. Currently available in areas of New Jersey.
Foundry — Elastic cloud infrastructure built for machine learning.
Avenzo Therapeutics — Developing the next generation of oncology therapies for patients.

Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Switzerland, Canada

Portfolio highlights

Nouscom — Nouscom is a next-generation immunotherapy company developing genetic cancer vaccines and oncolytic viruses..
Firefly Bio — Firefly specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.
Tentarix Biotherapeutics — Enabling intelligent therapies with multifunctional biologics.

3wVentures provides seed money and venture capital to international internet startups. As they focus on early stage projects and prototypes, our investments and co-investments target a volume of up to USD 250,000.

Investment focus

Software, Health Care, Information Technology
Seed, Angel, Series A
Switzerland, Spain, Austria

Portfolio highlights

Abionic — Abionic SA is ideally positioned at the boundaries of medical technology, biotechnology and nanotechnology. As a spin-off from EPFL (Swiss Federal Institute of Technology Lausanne, Switzerland), Abionic uses these highly advanced technologies to provide the medical profession with a novel diagnostic tool designed to give patients personal allergyprofiles. Abionic aims to become an important international player in the field of personalized medicine, in particular in allergy detection.Abionic SA is a certified ISO 9001/13485 company, including research, development and commercialization of in vitro diagnostic devices for allergies detection. The standard ISO 13485 specifies requirements for a quality management system where an organization has to demonstrate its ability to provide medical devices and related services that consistently meet customer and regulatory requirements.Abionic SA is a privately owned high-tech company and is strongly supported by the Swiss Federal Institute of Technology of Lausanne (EPFL), The Canton of Vaud and Venturelab.Abionic was founded by former scientists from the biomedical optics laboratory (LOB) at EPFL. Its headquarters are located in Lausanne, Switzerland.Abionic appreciates the support it has received from:
GUURU — Connect your customer community with your online shoppers to enable relevant, real-time advice from the people who love and use your products.
Pregnolia — Pregnolia ensures that every woman can have a happy, healthy and informed pregnancy until term. Their team knows that the existing research about preterm birth assessment is very promising, but this alone does not guarantee success. Sabrina, Francisco and Annette are highly committed to develop the commercial version of the device, complete theclinical trial, follow the regulatory roadmap and execute on their business vision to successfully support gynaecologists in improving the preterm birth risk assessment and birth management.

Eclosion assists entrepreneurs with the necessary resources to bridge the gap between their laboratories and the stage where the start-up

Investment focus

Biotechnology, Pharmaceutical, Health Care
Seed, Series C, Funding Round
Switzerland

Portfolio highlights

KYLYS — KYLYS is an innovative Swiss company based in Geneva founded in March 2017. KYLYS provides people and patients with highly effective and safe products based on biomolecules.
Genkyotex — Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage.Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.
MPC Therapeutics — MPC Therapeutics develops a novel class of compounds with application in Immunotherapy and Metabolic diseases

4FO Ventures

Investment focus

Artificial Intelligence, Health Care, Medical
Series A, Seed, Series B
Switzerland

Portfolio highlights

Positrigo — NeuroLF is an ultra-compact brain Positron Emission Tomography system. Our technology makes functional imaging accessible for people worldwide.
Ecorobotix — ecoRobotix contributes to an agriculture that respects the environment, focusing on soil and hydrological resources conservation and using a minimum amount of energy. ecoRobotix aims to offer precise, safe, reliable and affordable robotic solutions that simplify farmers’ life to produce healthy food. In particular, its revolutionary solar-poweredweeding robot offers a more sustainable use of herbicides while reducing farmers costs.
ARTIRIA Medical — Artiria Medical empowers catheters and guidewires. We develop cutting edge technologies to revolutionize the limits of neurointerventional procedures, enabling a seamless navigation and stroke treatment.

Polytech Ventures are an early stage VC firm based in Switzerland with a strong international focus. Their strategic location at EPFL in Lausanne grants us access to one of the most dynamic and recognized innovation centers in the world

Investment focus

Financial Services, FinTech, Software
Seed, Series A, Funding Round
Switzerland, United States, Spain

Portfolio highlights

yamo — Frische Bio-Kindernahrung von yamo, so lecker wie selbstgemacht und kostenlos direkt zu dir nach Hause geliefert. Jetzt probieren und profitieren.
Relai — Relai is a Bitcoin investment app that allows anyone to buy bitcoin within one minutes or set up an automated savings plan.
Earny — Payroll management built for Startups & SMEs. Swiss payroll service with no hidden fees & no hassle

GoBeyond is a FinTech company transforming angel investing into a new scalable asset class for small and large, novice to experienced investors. It offers a unique deal platform, portfolio tools, syndication/pooling, due diligence, investment monitoring services, training and certified deal leaders.Its clients are individuals, familyoffices, professional groups and corporations. It is active in the EU, Switzerland and the US. GoBeyond also offers educational training modules for angel investors in 11 categories.

Investment focus

Information Technology, Medical, Software
Funding Round, Seed, Series A
Switzerland, Germany, United Kingdom

Portfolio highlights

LEND — LEND provides peer to peer lending in Switzerland. It connects investors with borrowers. Moreover, investors earn substantial returns and borrowers benefit from low interest rates. The company is based in Switzerland and it was founded in 2015.
AVAtronics — AVA Active Noise Cancellation (ANC) Solution is a breakthrough in Audio Industry. AVA is the first and only TRUE WIDE-BAND ANC in the market capable of selectively cancelling all annoying noises we want to get rid of without compromising the quality of Music or speech.
Blumer — Blumer is a social networking platform that provides social networks that can monetize time by consuming advertisements, selling nfts, and making crypto transactions. It offers social networks, crypto, digital marketing, and blockchain.

Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.

Investment focus

Biotechnology, Health Care, Medical
Funding Round, Series B, Series A
Denmark, Sweden, Switzerland

Portfolio highlights

Kynexis — Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.
Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.
Rewind Therapeutics — Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.

Fongit Seed Invest (FSI) is the leading Seed Money Fund of Switzerland for young technology companies. It provides smart seed capital.

Investment focus

Health Care, Medical, Biotechnology
Seed, Series A, Series B
Switzerland

Portfolio highlights

EBAMed — EBAMed SA is a Swiss startup based in Geneva whose mission is to enable safe and effective non-invasive treatments of heart arrhythmias with protontherapy. The company is currently developing a medical device to enable non-invasive heart motion imaging and real-time synchronization of the therapeutic beam. This device consists in both hardware andsoftware components and expands treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients.
Gmelius — Gmelius is the world's first 360 email collaboration platform designed for Gmail and your company's daily apps. Join the async movement!
Annaida Technologies — Annaida Technologies has developed a groundbreaking device, EmbryoSpin, that performs microscopic Nuclear Magnetic Resonance (“µNMR”) at a scale 10-fold better than existing technologies.

How to Invest in Swiss Startups That Last The SICTIC Investor community helped to fund to more than 254 Swiss tech startups to date. While doing so, they learned a lot about what to watch out for and how to foster success. Read more Get your FREE angel handbook Services For Startups We invite all

Investment focus

Software, Artificial Intelligence, Information Technology
Seed, Pre-Seed, Funding Round
Switzerland, Germany, United Kingdom

Portfolio highlights

Gaia Tech — Gaia Technologies turns agricultural sidestreams into high-value ingredients for cosmetics, food, and feed manufacturers.
PeriVision — At Perivision, we combine artificial intelligence (AI), virtual reality (VR) and the cloud to build the next generation systems to understand visual function. Our systems improve workflow efficiency in practices and hospitals and provide deeper clinical insight into eye diseases.
Health Yourself — Health Yourself is making routine healthcare services available digitally and from home. So far, we are offering lab tests from home, medication subscriptions and personalised supplements for health concerns ranging from sexual health to prevention.

Endeavour Vision is an investment advisory firm focused on transformative healthcare technologies.

Investment focus

Health Care, Medical, Biotechnology
Series C, Series B, Series A
United States, Switzerland, France

Portfolio highlights

Venture Med Group — VentureMed Group (VMG) designs, develops and markets innovative medical devices which enable interventionalists to cost effectively treat peripheral artery diseases and improve the lives of their patients.Founded by physicians who understand the clinical, medical and financial demands in today’s healthcare environment, VMG creates truly costeffective solutions. Their flagship product, the FLEX Scoring Catheter enables providers to reduce expensive inventory costs while offering the interventionalist more treatment options from a single device.
Relievant Medsystems — Relievant's mission is to provide patients with low risk therapy that can alleviate their back pain.
Virtual Incision — Virtual Incision is reimagining robotic support for minimally invasive (MIS) procedures with simple innovations offering mobility, flexibility, and accessibility to provide MIS options to more patients. It has develops the MIRA® (Miniaturized In vivo Robotic Assistant) Platform, a first-of-its-kind miniaturized surgical robotic support device,focusing first on colon resection, with follow-on specialty robots for additional potential applications.

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Switzerland, United Kingdom

Portfolio highlights

Nouscom — Nouscom is a next-generation immunotherapy company developing genetic cancer vaccines and oncolytic viruses..
DISCO Pharmaceuticals — DISCO Pharmaceuticals is a firm that specializes in large-scale surfaceome unlocking of cancer cells.
Polaris Electro-Optics — Polaris Electro-Optics empowers integrated photonics for communications and computation.

Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, China, Israel

Portfolio highlights

Avalo Therapeutics — Avalo Therapeutics is a clinical-stage biopharmaceutical company that employs a precision medicine approach to discover, develop, and commercialize highly targeted therapeutics in areas of significant unmet clinical need.
Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
Alterome Therapeutics — Transforming the lives of cancer patients, one alteration at a time. Our Mission is to discover precise therapies and inspire hope for individuals affected by cancer.

Bernina BioInvest is an investment Firm.

Investment focus

Biotechnology, Health Care, Biopharma
Seed, Series A, Series B
Switzerland

Portfolio highlights

HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
Memo Therapeutics — Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.
Synendos Therapeutics — Synendos Therapeutics is a biopharmaceutical company that aims to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of natural functioning of the brain.

Wingman Ventures is Switzerland’s leading pre-seed fund backing founder teams building tech companies with the potential to become global market leaders. We have a track-record of supporting exceptional founders in creating breakthrough companies and it is our passionate conviction that the Swiss startup ecosystem is just starting to write its bestsuccess stories.As founders, we always valued feedback from experienced entrepreneurs. In fact, it was critical to our success.Wanting to dedicate our know-how, experience and energy to the new generation of startup founders, we founded Wingman Ventures. As wingmen and wingmates we fly on the wings of ambitious founder teams and help them navigate around storms and avoid severe turbulences on their way to building successful companies.

Investment focus

Software, Artificial Intelligence, SaaS
Seed, Pre-Seed, Series A
Switzerland, United Kingdom, Canada

Portfolio highlights

Nala Earth — Nala empowers companies to measure, manage and report their impact and dependency on nature - compliant with regulation.
Chiral — Next-generation electronics with nanomaterials
Cultivated Biosciences — Cultivated - Creamy, dairy-free indulgence

Broadview Ventures, Inc. (Broadview) was established in 2008 as a new program conceived by the Leducq family. Through Broadview, the trust will work to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investment in and support of early stage technology ventures.The FoundationLeducq, based in Paris, France, is the beneficiary of a charitable trust. In order to further the Foundation Leducq's mission in cardiovascular and neurovascular disease, the trust has made funds available to Broadview to develop a program which will promote early state technology in these fields through investments, licensing agreements and consortium funding arrangements, as well as professional, management and consulting support.With this initiative the trust joins other leaders in the venture philanthropy movement in seeking creative solutions to the problem of what is commonly referred to as the 'translational gap', a significant component of which is a lack of funding at a critical moment in the development of new technology and science.

Investment focus

Health Care, Biotechnology, Medical Device
Series A, Seed, Debt Financing
United States, Israel, Denmark

Portfolio highlights

IsomAb — IsomAb evaluate and develop isoform specific antibodies to treat disease.
Nyra Medical — MitraPlug has created a catheter-plug technology for repairing a leaky mitral valve in the heart.This adjustable device needs only a two-inch surgical incision and can be inserted directly into the heart. Then the cardiologist can use the catheter to adjust the size and position of the plug to correct the leakage. When correctly fitted, thecatheter is removed, and the incision is closed, leaving only a small scar.
Cardiosense — Cardiosense offers a physiological waveform AI platform to develop predictive biomarkers for the detection and treatment of disease. Its platform leverages multi-modal sensors and industry-leading AI to develop predictive biomarkers for the detection and treatment of disease.

Zühlke Ventures AG is a venture capital arm of Zühlke Technology Group AG specializing in financing of start-ups at an early stage and providing growth capital. It seeks to invest in the technology and medical devices companies. It typically invests in German-speaking Europe and Great Britain.

Investment focus

Health Care, Medical Device, Biotechnology
Series A, Seed, Series B
Switzerland, Sweden, United States

Portfolio highlights

Evismo — Evismo provides diagnostics services in Switzerland
Healios AG — Healios CTMS provides the Digital Biomarker based technology and digital validation scales to improve and streamline research and clinical practice.
Flow Neuroscience — Flow Neuroscience is a healthcare company that develops depression treatment devices that combines an easy-to-use brain stimulation headset with a personalized mobile app to target both the physical and behavioral elements of Major Depressive Disorder (MDD). The company's wearable stimulates a patient's left frontal lobe, the area of thebrain that has often lowered activity in people suffering from depression.Flow Neuroscience combines their wearable with a mobile app that nudges users to behaviors that will help lessen the effects of their depression, including exercise and regular sleeping patterns.The company's hope is to make available for the public a treatment that's currently only used in clinics specialized in brain stimulation. It also wants to make the treatment affordable enough to seriously challenge a dominant pharmaceuticals industry.

Index Ventures is an international venture capital firm with dual headquarters in San Francisco and London, investing in technology-enabled companies with a focus on e-commerce, fintech, mobility, gaming, infrastructure/AI, and security.

Investment focus

Software, E-Commerce, Internet
Series A, Series B, Seed
United States, United Kingdom, France

Portfolio highlights

SESO — Seso is a labor solution for agriculture. We provide support with the entire H-2A process, including the H-2A Visa, recruiting farmworkers, H-2A compliance, and digital worker onboarding.
Vizcom — Vizcom is an Ai-powered creative tool designed for design and creative professionals. It offers a transformative approach to concept drawing, enabling users to turn their sketches into impressive realistic renderings quickly and efficiently.
Nourish — Achieve your desired health and wellness through personalized nutrition counseling. Nourish is the easiest way to find a registered dietitian and get it covered by your insurance. Find a dietitian today and start your telehealth appointments.

Vinci Capital is a leading Swiss private equity firm with over MCHF 200 under management. Since 1998 they have provided equity to over 30 Swiss technology and industrial companies to finance innovation, growth and succession-buyouts.Their investment team capitalizes on 40 years of cumulated experience in private equity and a solid operationalbackground in growth, turn-around, consolidation, IPOs and M&A situations.

Investment focus

Medical, Health Care, Biotechnology
Series A, Series B, Funding Round
Switzerland, Germany

Portfolio highlights

Anergis — Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne inSwitzerland.
SENSIMED — Sensimed designs, develops, and commercializes integrated micro-systems for medical devices. The company’s product portfolio includes SENSIMED Triggerfish, a product that offers an automated recoding of continuous ocular dimensional change over 24 hours. Sensimed is now focused on expanding the knowledge of how this individual data can best beused in the clinical setting to deliver customized treatment. The 24 hour profiles are being centralized on a registry together with patient and treatment information. The data is being analyzed and modeled on an ongoing basis in an attempt to identifying pathological patterns that can be used to differentiate indication, personalize treatment and assess efficacy following treatment.Sensimed was founded by Matteo Leonardi and Sacha Cerboni in August 2003 and is based in Lausanne, Switzerland.
Beqom — beqom is a Total Compensation Management Software Solution focused exclusively on managing compensation & performance for HR & Sales.

EIT Health is a network of best-in-class health innovators backed by the EU. We deliver solutions to enable European citizens to live longer, healthier lives.

Investment focus

Health Care, Medical Device, Medical
Grant, Pre-Seed, Seed
United Kingdom, Spain, Ireland

Portfolio highlights

Ochre Bio — Ochre Bio is developing therapies for the biggest liver health challenges.
Trak — Do you know TRAK's tele rehabilitation software? Get more clinical performance and grow your physical therapy business, request a trial!
Nanordica Medical — Nanordica Medical develops novel nanoparticle-based antibacterial wound care products.

Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcareservices. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.

Investment focus

Biotechnology, Health Care, Medical
Series C, Series B, Series A
United States, The Netherlands, Germany

Portfolio highlights

ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
Argá Medtech — Developing the next generation of Pulsed Field Ablation and Irreversible Electroporation Venture-capital backed company
GT Medical Technologies — At GT Medical Technologies, our purpose is Improving the Lives of Patients with Brain Tumors. GammaTile Therapy is Surgically Targeted Radiation Therapy (STaRT) for patients with brain tumors.

Inserm Transfert Initiative is a seed stage life science vehicle currently managing about â‚¬4.2M for the financing of new biotech companies. Inserm Transfert Initiative is the new investment vehicle of INSERM in France.

Investment focus

Biotechnology, Medical, Health Care
Series A, Series B, Seed
France, Switzerland, United States

Portfolio highlights

Eyevensys — Eyevensys is a address critical unmet needs in ophthalmology by providing a much better way of delivering ophthalmic drugs that overcomes the limitations of current options, such as intravitreal injections, surgery, intravitreal implants and biodegradable formulations. All of these current options have their drawbacks, given they are invasiveprocedures. Eyevensys’ goal is not only to improve short and long term therapeutic outcomes, but also to enhance compliance, improve ocular bioavailability and tolerability.They plan to build a high value product pipeline by enabling sustained production of therapeutic proteins in the eye that will deliver improved clinical outcomes while reducing the burden of frequent intravitreal or systemic injections and other invasive procedures.
VectivBio — We Are Ironwood
Aelis Farma — Aelis Farma is a pioneer in the development of signaling specific therapeutics that target GPCRs (and more specifically the CB1 receptor which is one of the most expressed GPCRs in the brain). GPCRs are the target of most therapeutic drugs. This family of receptors has the characteristics to activate several and often opposing signaling pathways.Unfortunately, most of the drugs acting on GPCRs either block or stimulate the entire signaling activity of the receptor resulting in unwanted and sometimes unacceptable side effects.

EQT life science develops innovative medicines, devices, and tools to address the single important thing that matters to the preservation of health. The organization believes that such opportunities add value to all stakeholders.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, The Netherlands, Switzerland

Portfolio highlights

Onera Health — Introduction to Onera sleep diagnostics and monitoring solutions
Vico Therapeutics — Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarilyaffecting girls that enable clients with providing therapy for it.Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands.
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and

Alpana Ventures is a Swiss VC focusing on digital transformation.Since 2016 we backed 45 founder teams with 3 Funds, supporting them in their journey towards a positive impact.Committed to value creation, we discover deep tech solutions in Switzerland, Europe and the US.We invest to embed them into innovative business models and back them tobecome global market leaders.Applying ESG criteria, our portfolio companies help create a more sustainable future.

Investment focus

Software, FinTech, Information Technology
Seed, Series A, Funding Round
United States, Switzerland, Germany

Portfolio highlights

Sinay — Use the full potential of your data with intelligent solutions. Become more efficient on a daily basis and reduce your environmental impact.
Nezasa — Nezasa’s travel booking solution empowers travel brands globally to combine all planning and booking related actions into one seamless end-to-end experience.Our tools, enable to plan and book any type of multi-product or multi-stop itinerary.TripBuilder Hyper-personalised packaging Real-time planning and booking of personalised itinerariesPowerful, easy to use and very interactive Deep integration possibilities into existing fulfilment landscapes Enterprise-grade, proven with large TO customersTripBooster Hyper-personalised In-Destination Upselling The extension of TripBuilder’s power throughout the entire travel lifecycle The perfect travel companion Seamless purchasing of perfectly fitting additional products Smart upselling recommendation, available in both a push and pull mode
Tinamu — Tinamu Labs has developed a technology that converts commercially available drones into camera equipment reaching professional standards.

Schroders Capital provides investors with access to a broad range of private asset investment opportunities, portfolio building blocks and customised private asset strategies. With over $65 billion assets under management, we offer a diversified range of investment strategies, including real estate, private equity, secondaries, venture capital, infrastructure, securitised products and asset-based finance, insurance-linked securities and impact investing.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series C, Series A
Switzerland, United States, India

Portfolio highlights

Lenskart — Lenskart, the first of its kind online optical store in India, has made it possible to acquire a good quality pair of specs with prescription lenses for just Rs. 399, all this while you sit in the comfort of your home. With a 48-hour free home delivery guarantee and 365 days return policy, Lenskart.com is doing what e-commerce hasn’t been able todo in India yet.The website has over 500 designs of eye frames, in multiple colors, for all age groups, from Rs. 399 all the way to Rs. 4,000 for a pair. All one needs to do is select a frame, fill in their power, and place an order. You can pay online or at the time of delivery.Lenskart.com has the biggest collection of discounted contact lenses consisting of all top-notch brands (viz. Johnson & Johnson, Bausch & Lomb, Ciba Vision are to name a few) and be it disposable, toric, colored or bifocal contact lenses, you can find all possible types here. Lenskart is dedicated to providing its customers with a simple, hassle-free way to replace their contact lenses. One can receive the exact same contact lens, their doctor prescribed, delivered to their door, at a great price.
HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.

Grazia Equity is a venture Capital firm investing in innovative, technology driven startups with high potential.Based in Stuttgart (Germany), Grazia has been supporting a large number of mostly young companies, often from their foundation to the Initial Public Offering or eventual sale. In contrast to other venture capital firms, theypredominantly work with their own capital that they invest as entrepreneurs.

Investment focus

Internet, E-Commerce, Biotechnology
Series A, Seed, Series B
Germany, United States, Switzerland

Portfolio highlights

VYTAL — Start the Packaging Revolution! We are offering smart & reusable To-Go Packaging-as-a-Service to gastronomy clients & consumers.In Germany the consumption of take-away, convenience and delivery food & drinks is responsible for about 281 kilotons of single-use packaging waste for immediate consumption and is growing at double digitrates. Most of the time, To-Go food containers, snack boxes or coffee cups have a very short life-span of only 30 minutes after which they are tossed into trash (or litter parks, beaches & the ocean). This is not only a giant waste of economic resources as each single use costs between 15 and up to 0,60€ for a stable bowl/box with a lid. It is a horrendous waste of environmental resources (wood, water, crude oil, metals & energy) that are used to produce this packaging. Therefore, a single use packaging not weighing more than 30 grams can easily come with an ecological backpack of more than 8 kilograms when taking into account all the resources used in production (material intensities taken from Wuppertal Institute for Climate, Environment and Energy). Looking at GHG emissions, the picture is similarly bleak: Using CO2 emission factors and the detailed material mix of the single-use packaging waste analyzed by NABU (German Nature and Biodiversity Conservation Union), the 281 thousand tons waste from To-Go consumption generated around 556 thousand tons of CO2 or the equivalent of 195k passenger cars per year (assuming an average distance travelled of 15,000km). With the expected rise of take-away, convenience and delivery food, the related emissions are expected to increase at double digit rates as waste volume is expected to increase and as we saw a shift to plastics relative to cardboard or other materials. While there is a growing awareness of the problem, especially in Germany, there is no scalable solution yet and the commonly used alternative of nature-based & ‘biodegradable’ materials like bagasse or PLA also require many resources for production & transport, and have to be incinerated or go to landfill after use as there is currently no way to compost them.
ZAGENO — ZAGENO is a multi-vendor, online marketplace of life science products which, by simplifying the procurement process, saves more time for science.
Hypatos — Manual document processing is a major cost driver. Hypatos' deep learning tech automates complex document processing tasks. Make back office more efficient!

Baszucki Group directs resources toward the greater good through mission-driven investments that improve human health, governance, and the health of our planet.

Investment focus

Medical, Health Care, Biotechnology
Seed
Switzerland

Portfolio highlights

KetoSwiss — KetoSwiss is a Swiss-based BioTech startup that strives to bring ketone bodies back into the modern world to combat diseases. It develops and clinically tests a novel nutraceutical/medical food for the dietary preventive therapy of higher-frequency migraines and possibly other related neurological diseases characterized by a metabolicdysfunction (such as Alzheimer's disease). KetoSwiss is headquartered at the Technologie Park Basel, in Basel Switzerland, where it is part of a dynamic scientific and entrepreneurial community composed of world-leading academic research laboratories, flourishing life sciences spin-offs and s world-leading biotech-startup-ecosystem.

Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.Bpifrance was founded in 2012 and is based in Maisons-alfort, Ile-de-France,France.

Investment focus

Software, Information Technology, Health Care
Funding Round, Seed, Series A
France, United States, Switzerland

Portfolio highlights

HawkCell — A plug-and-play solution turning human MRI into the first animal-dedicated imaging enhanced with AI algorithms. A unique MRI solution.
Unseenlabs — Unseenlabs designs and develops a spectrum surveillance payload which is designed to detect and track non-cooperative vessels wherever they happen to be in the world.
Docent — Docent is the first AI-powered mobile application to offer a fully-personalized experience for discovering, accessing and collecting contemporary masterpieces.

Reference Capital is a privately held advisory firm dedicated to researching and investing in disruptive technologies which will transform the world we live in. Our team is composed of seasoned VC investors and family office managers primarily based in Geneva, Switzerland.

Investment focus

Software, Health Care, Biotechnology
Series A, Series C, Series B
United States, Switzerland, United Kingdom

Portfolio highlights

Wayve — Wayve are pioneering an AI-centric approach to self-driving, inspired by our vision of a smarter, safer and more sustainable world.
All Day Kitchens — Virtual Kitchen operates as a platform that empowers restaurants to take full advantage of the delivery opportunity. Its delivery-optimized kitchens and technology unlock delivery coverage with minimal upfront investment. The company was founded in 2018 and is headquartered in San Francisco, California.
Kingdom Supercultures — Kingdom Supercultures create microbial cultures that help food manufacturers to create new foods with boosted benefits. It re-assembles nature's microbes into new combinations, creating plant-based foods that taste like dairy, low-alcohol beverages with full flavor, and natural preservatives that work as well as artificial ones.They workwith clients across diverse industries including food, beverage, personal care, beauty, and more. Their technology comprises an expansive biobank of GRAS microbial strains, high-resolution strain characterization, and new algorithms for predicting and assembling microbial communities.

The William K. Warren Foundation focuses on people and aims to improve the human condition on earth as a response to and in thanksgiving.The foundation's goal is to make medical care available to all patients utilizing Saint Francis Health System, and to this end, it annually supports various medical programs. In addition to the hospitalsand clinics, the foundation created The William K. Warren Medical Research Centre in 1973, which provides funds to medical investigators who participate in advanced medical research and creates environments that allow for the best possible delivery of care.

Investment focus

Machine Learning, Health Care, Artificial Intelligence
Seed, Series A, Series B
United States, Switzerland

Portfolio highlights

KetoSwiss — KetoSwiss is a Swiss-based BioTech startup that strives to bring ketone bodies back into the modern world to combat diseases. It develops and clinically tests a novel nutraceutical/medical food for the dietary preventive therapy of higher-frequency migraines and possibly other related neurological diseases characterized by a metabolicdysfunction (such as Alzheimer's disease). KetoSwiss is headquartered at the Technologie Park Basel, in Basel Switzerland, where it is part of a dynamic scientific and entrepreneurial community composed of world-leading academic research laboratories, flourishing life sciences spin-offs and s world-leading biotech-startup-ecosystem.
Spring Health — Eliminating barriers to mental healthcare. Clinically-proven technology with world-class providers to deliver precisely what your employees need.
iRecommend Software™ — iRecommend Software™ develops intelligent business solutions utilizing artificial intelligence (AI), machine learning, and dynamic data modeling.In a consumer-driven economy, businesses across all industries, are facing the challenge to remain relevant and provide highly personalized products and services.iRecommend's leading solution,Recommendation360™ is a recommendation engine with applications across multiple industries, including recruiting, real estate, retail/e-commerce, entertainment, travel, government, and healthcare. These industry-specific solutions enable businesses to generate hyper-personalized recommendations of products and services for their customers. Recommendation360's proprietary technology rapidly aggregates and analyzes millions of data points from the public domain to provide the right products or services to the right person at the right time. Headquartered in Tulsa, Oklahoma with offices in Oklahoma City, New York, San Francisco, London, and Dubai.

VI Partners are Venture Capitalists successfully financing outstanding teams and innovations in the Healthcare and Technology space since 20 years.

Investment focus

Health Care, Biotechnology, Medical Device
Series A, Series B, Series C
Switzerland, Germany, United States

Portfolio highlights

Xeltis — Xeltis is pioneering a restorative approach in cardiovascular therapy.
LeaseTeq — LeaseTeq bietet Privat- sowie Unternehmenskunden das erste komplett digitale Leasingangebot.
Unique — Try Unique Finance GPT to increase productivity by automating manual workload through AI and ChatGPT solutions.

Viva BioInnovator (VBI) is the specialized investment and incubation arm of Viva Biotech Holdings. We focus on the initial creation and development of biotech startups across all indications and drug types. During the early stages of drug discovery, we can nurture and accelerate a startup's growth from idea to clinical program. VBI'sunique investment and incubation model started out of necessity in 2014. Our roots are in drug discovery services, where we operate world-leading and proprietary drug discovery platforms. While serving big pharma customers from around the globe, we came to realize the huge demand from many entrepreneurs who have great ideas but cannot receive funding to advance their plan due to lack of data. We saw the value in many of these innovative ideas and provided our CRO drug discovery services, operational support, and monetary backing to help these creative scientists embark on the "0 to 1" transformation. This spark launched our "equity for service (EFS)" investment and incubation model. VBI is based in Shanghai, with an office in Boston and personnel in California. As of early 2019, VBI has invested in over 30 companies out of the hundreds of proposals submitted for review and we plan to invest at a rapid pace in the years to come. The majority of our current portfolio companies are US based, but we are open to proposals globally and are excited to see new ideas that fit our investment strategy. If you would like to learn more about us, please visit: www.vivabioinnovator.com Or send an email to innovation@vivabiotech.com If you would like to learn more about our parent company, Viva Biotech, please visit: www.vivabiotech.com

Investment focus

Biotechnology, Health Care, Therapeutics
Seed, Series A, Series B
United States, Canada, Switzerland

Portfolio highlights

ArrePath — ArrePath is an anti-infective drug discovery company addressing the global health challenge of drug resistant infections.
Deka Biosciences — Deka BioSciences, Inc. is committed to developing and delivering life-changing medicines to patients with cancer and inflammatory diseases.
HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.

R42 Group is a venture fund and an institute which invents, invests and informs covering AI, deep science, 5G mobile, biotech and fintech.

Investment focus

Biotechnology, Health Care, Information Technology
Seed, Funding Round, Pre-Seed
United Kingdom, United States, Austria

Portfolio highlights

Senisca — Developing a new generation of senotherapeutic interventions to target the diseases and aesthetic signs of ageing.
KetoSwiss — KetoSwiss is a Swiss-based BioTech startup that strives to bring ketone bodies back into the modern world to combat diseases. It develops and clinically tests a novel nutraceutical/medical food for the dietary preventive therapy of higher-frequency migraines and possibly other related neurological diseases characterized by a metabolicdysfunction (such as Alzheimer's disease). KetoSwiss is headquartered at the Technologie Park Basel, in Basel Switzerland, where it is part of a dynamic scientific and entrepreneurial community composed of world-leading academic research laboratories, flourishing life sciences spin-offs and s world-leading biotech-startup-ecosystem.
Reservoir Neuroscience — Reservoir Neuroscience is a biopharma company that develops novel therapeutics to repair dysfunctional blood vessels in the brain. Reservoir Neuroscience was founded in 2019 and is based in Emeryville, California.

EVA is sparring partner for new entrepreneurs in the Life Sciences with planned base in north-western SwitzerlandThey support start-ups by helping to bridge the gap between their business idea and the successful commercialization of their life sciences projects, innovations and technologies.They provide thorough coaching and activelyencourage contact with their wide-ranging network of experts and investors as well as providing seed-phase investments.In science and technology transfer, they act as the link between researchers, universities’ scientific liaison offices, potential investors and the market.

Investment focus

Biotechnology, Medical Device, Medical
Seed, Series A
Switzerland

Portfolio highlights

AOT - Advanced Osteotomy Tools — AOT AG is a privately owned Swiss Robotic Surgery company, which spun out of the University Hospital and the University Basel (Switzerland) in 2011 and was first funded in 2012. The company is dedicated to the development, manufacturing and sales of medical devices for osteotomy pursuing the vision of contact-free bone surgery using laser,robotics and navigation systems to re-invent bone surgery (osteotomy).
POLYNEURON — Polyneuron is a developer of novel therapeutics intended to facilitate the treatment of antibody-mediated autoimmune diseases. The company's biodegradable glycopolymers-based therapeutics selectively eliminate the pathological autoantibodies, while leaving the rest of the immune system intact, enabling medical practitioners to treat patientswith immune disorders in a safe and effective manner.
Memo Therapeutics — Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.

Innosuisse’s role is to promote science-based innovation in the interests of industry and society in Switzerland.

Investment focus

Health Care, Biotechnology, Medical Device
Grant, Pre-Seed, Seed
Switzerland, United States, Taiwan

Portfolio highlights

Pelt8 — Pelt8 enables climate action through the platform with scalable processes and controls to collect sustainability-related data in an easy and traceable way.
Atinary — Atinary is an end-to-end AI, machine learning, robotics, and cloud computing technology platform for digitizing R&D operations.
Ascento — Secure, maintain, and inspect outdoor assets by reducing the intervention times and augmenting data capturing capability.

Boundary Holding is a European deep tech investment firm with presence in Luxembourg and France that invests in technologies enabling 4th industrial revolution.

Investment focus

Drones, Robotics, Artificial Intelligence
Seed, Series A, Series B
Switzerland, India, France

Portfolio highlights

Aero41 — Aero41 is developing a drone entirely dedicated to crop protection, a flexible and intelligent platform that will integrate AI and collect data to make crop protection more and more eco-responsible while being effective to ensure the necessary yields.
Neo Medical — Neo aims at transforming the current approach to spinal surgery by providing a unique answer to the worldwide strive for healthcare cost optimization through efficient, versatile and high quality systems.
Remidio Innovative Solutions — Remidio is engaged in designing & developing Smart, Innovative & Disruptive Imaging Technologies in Vision Care, using a product development approach called “Design Thinking”.As part of the Design Thinking process, Remidio takes into account different facets of a customer’s experience with a product, as part of its overall productdesign approach, with the intent of inventing a new customer experience with the product.Customers can be an amazing resource to glean insight and understanding, but they are generally not able to articulate their latent and anticipated needs. Remidio hence focuses on making quick functional prototypes, that can then be given to the customer to understand these latent needs while observing their use of the prototypes.Founded by professionals with a passion for product innovation, Remidio is currently focussed on creating game changing products and solutions in the ophthalmology space.We look at constraints posed by a developing nation context- infrastructure, skilled resources and affordable pricing as an opportunity to innovate.We bring to market very high quality products that are reliable and extremely simple to use.

Leading #lifesciences #venturecapital firm financing highly #innovative #biotechnology companies #worlwide.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
Spain, United States, Switzerland

Portfolio highlights

VarmX — VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.
Xeltis — Xeltis is pioneering a restorative approach in cardiovascular therapy.
Kynexis — Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.

Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, Switzerland, United Kingdom

Portfolio highlights

Hyku — Hyku Biosciences is developing the next generation of covalent medicines by targeting histidine, tyrosine and lysine binding pockets in disease-causing proteins.
Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
Hepalink — Hepalink is a manufactures ultra-pure pipeline control systems based on semiconductors and pan-semiconductor liquid circuits.

Boosting health pioneers. We invest in early stage start-ups in different sectors: medtech, life science, biotech, mental health, public health, well-being.

Investment focus

Medical, Health Care, Biotechnology
Seed, Series A
Switzerland

Portfolio highlights

Microcaps — Microcaps provides a novel solution to encapsulate ingredients naturally, protect them an enhance them with high-end appearence
Healios AG — Healios CTMS provides the Digital Biomarker based technology and digital validation scales to improve and streamline research and clinical practice.
MUVON Therapeutics — Muvon Therapeutics platform helps women with urinary incontinence and treats diseases based on skeletal muscle degradation, supporting them in their commitment to living a healthy life. The company's mode of contact is by mail, phone, and physical address.

Healthspan Capital is an early-stage longevity venture capital firm that invests in biotechnology startups developing therapies to slow or reverse aging.

Investment focus

Health Care, Medical, Software
Seed
Germany, Switzerland

Portfolio highlights

KetoSwiss — KetoSwiss is a Swiss-based BioTech startup that strives to bring ketone bodies back into the modern world to combat diseases. It develops and clinically tests a novel nutraceutical/medical food for the dietary preventive therapy of higher-frequency migraines and possibly other related neurological diseases characterized by a metabolicdysfunction (such as Alzheimer's disease). KetoSwiss is headquartered at the Technologie Park Basel, in Basel Switzerland, where it is part of a dynamic scientific and entrepreneurial community composed of world-leading academic research laboratories, flourishing life sciences spin-offs and s world-leading biotech-startup-ecosystem.
Molecule — Molecule is a collaborative platform, where stakeholders in drug development work together to accelerate the process of bringing novel therapeutics to patients. We connect leading researchers to investment opportunities by turning intellectual property and its development into a liquid and easily investable asset.
Reservoir Neuroscience — Reservoir Neuroscience is a biopharma company that develops novel therapeutics to repair dysfunctional blood vessels in the brain. Reservoir Neuroscience was founded in 2019 and is based in Emeryville, California.

The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Germany, Belgium

Portfolio highlights

Actym Therapeutics, Inc. — Actym Therapeutics is developing key biotech to help target intractable immune pathways in the tumor microenvironment.
smartbax — We develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
Glox Therapeutics — Developing novel precision antibiotics based on protein bacteriocins, to target Gram-negative Antimicrobial Resistant (AMR) pathogens.

Ortho Innovations is a manufacturer of orthopedic products. The company's products are the elbow brace, knee brace, hyperflexion elbow, wrist, flexion-extension, wrist pronation, supination, and hip abduction orthosis.

Investment focus

Medical, Health Care, Biotechnology
Seed
Switzerland

Portfolio highlights

KetoSwiss — KetoSwiss is a Swiss-based BioTech startup that strives to bring ketone bodies back into the modern world to combat diseases. It develops and clinically tests a novel nutraceutical/medical food for the dietary preventive therapy of higher-frequency migraines and possibly other related neurological diseases characterized by a metabolicdysfunction (such as Alzheimer's disease). KetoSwiss is headquartered at the Technologie Park Basel, in Basel Switzerland, where it is part of a dynamic scientific and entrepreneurial community composed of world-leading academic research laboratories, flourishing life sciences spin-offs and s world-leading biotech-startup-ecosystem.

Investors by industry

Media (entertainment)

EdTech

Consumer

Climate